USITC Finds Patent Violation in Photodynamic Therapy Case, Issues Import Ban

You might care about this because the US International Trade Commission, or ITC, has made an important ruling. They found that certain companies violated Section 337 of the Tariff Act. This law stops unfair practices in import trade. In this specific case, the violation involved photodynamic therapy systems, their parts, and medicines used with them. These items were found to be infringing on patents owned by Sun Pharmaceutical Industries. The ITC issued a "limited exclusion order." This order bans the entry of these infringing products made by the respondent companies into the United States. They also issued "cease and desist orders." These orders tell the companies to stop selling these products. This investigation involved Sun Pharmaceutical Industries as the company making the complaint. The companies named as respondents included Biofrontera Inc., Biofrontera Pharma GmbH, Biofrontera Bioscience GmbH, and Biofrontera AG. The patents involved were U.S. Patent Nos. 11,446,512 and 11,697,028. The ITC's decision means that Sun Pharmaceutical successfully showed that the Biofrontera companies were importing products that violated their patents. The case also touched on whether Sun Pharmaceutical had a domestic industry that relied on these patents. This is a requirement for Section 337 cases. The ITC confirmed that the domestic industry requirement was met. This ruling protects American businesses from foreign companies importing products that unlawfully copy their patented technology. What makes this case particularly interesting is how the legal process unfolded, especially concerning the validity of the patents. Even though the ITC found a patent violation and issued orders to stop imports, they also made a special decision regarding one of the patents. The ITC chose to suspend the orders related to the '028 patent. This suspension happened because a different government body, the US Patent and Trademark Office's Patent Trial and Appeal Board, issued a preliminary decision. This board suggested that some claims of the '028 patent might not be valid because they were obvious. This shows a real-time interaction between different legal authorities. It highlights that patent disputes can have many layers. A patent might be considered infringed in one proceeding, but its very validity can be questioned in another. This situation creates a dynamic legal environment. It means that the outcome for companies can change based on decisions from various courts and boards. This specific case shows how complex patent law can be and how quickly circumstances can shift in these types of disputes. It also underscores the ongoing challenges companies face in protecting their intellectual property from competitors. People and groups who would find this legal document highly relevant include companies that own patents, especially those in the pharmaceutical and medical device industries. Businesses that rely on intellectual property to protect their products and innovations should pay close attention. Importers and exporters of goods into the United States, particularly those dealing with technology or patented components, also need to understand these rules. Lawyers specializing in patent law, international trade law, and intellectual property will find the details of this case valuable for their practice. Legal scholars and students studying trade law or patent litigation will see this as an example of how Section 337 investigations are carried out and how different legal decisions can interact. Anyone involved in the photodynamic therapy field, whether as a researcher, manufacturer, or investor, would also be interested. This is because the ruling directly affects the market for these specific medical systems and products. Finally, this document is relevant to anyone who follows how US trade laws are used to protect domestic industries from unfair competition from imported goods.